Cholesterol level goal attainment with statins: Clinical management guideline recommendations versus management in actual clinical practice

Pharmacotherapy

Volumn 32, Issue 7, 2012, Pages 631-641

  Heintjes, Edith M ^a   Penning van Beest, Fernie J A ^a   Plat, Arian W ^a   Meerding, Willem Jan ^b   Webb, Kate ^c   Sturkenboom, Miriam C ^d   Herings, Ron M C ^a,d  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adherence; Atorvastatin; Goal attainment; Guidelines; Policies; Pravastatin; Rosuvastatin; Simvastatin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; COST CONTROL; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG USE; FEMALE; FOLLOW UP; GOAL ATTAINMENT; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; PRAVASTATIN; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; RISK; SIMVASTATIN; SULFONAMIDES;

EID: 84864616703     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2011.01086.x     Document Type: Article

References (38)

1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376(9753):1670-81.
2. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clin Ther 2009;31(2):236-44.
3. LaRosa JC. New and emerging data from clinical trials of statins. Curr Atheroscler Rep 2004;6(1):12-9.
4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003;326 (7404):1423.
5. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: The risk curve concept. Am J Cardiol 2006;98(10):1405-8.
6. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24(17):1601-10.
7. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Eur Heart J 2007;28(19):2375-414.
8. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19(10):1434-503.
9. Moon JC, Bogle RG. Switching statins. BMJ 2006;332(7554): 1344-5.
10. National Institute for Health and Clinical Excellence (NICE). Statins for the prevention of cardiovascular events. National Institutes of Health and Excellence, United Kingdom, 2006.
11. Moon J, Grosso A, MacAllister R, Hingorani A. University College London Hospitals Guidelines on statin prescribing in the prevention of cardiovascular disease. NHS Foundation Trust, use of medicines committee, London, 2006.
12. Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: A nationwide prescription study. Br J Clin Pharmacol 2007;64 (4):476-81.
13. Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: A register-based study. Med Care 2010;48(9):761-6.
14. Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: Implications for the future. Expert Rev Pharmacoecon Outcomes Res 2009;9 (5):475-84.
15. Zorgverzekeraars N. Beleidsdocument aanwijzing preferente geneesmiddelen [Policy document designating preferential medications]. Staatscourant 2005 2 May 2005;Sect. 28-32.
16. Kengetallen SF. Nieuwe voorwaarden cholesterolverlagers [new conditions cholesterol lowering drugs]. Pharmaceutisch Weekblad 2008;143(50):11.
17. CBO/NHG. Multidisciplinaire richtlijn Cardiovasculair Risicomanagement. Utrecht: Kwaliteitsinstituut voor de gezondheidszorg CBO en Nederlands Huisartsen Genootschap 2006. Report No.: ISBN 10: 90-8523-131-0; ISBN 13: 978-90-8523- 131-8.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
19. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339(19):1349-57.
20. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361(9364):1149-58.
21. Heintjes EM, Hirsch MW, van der Linden MW, O'Donnell JC, Stalenhoef AF, Herings RM. LDL-C reductions and goal attainment among naive statin users in the Netherlands: Real life results. Curr Med Res Opin 2008;24(8):2241-50.
22. Goettsch WG, Yin DD, Alemao E, Klungel OH, Stalenhoef AF, Herings RM. Statins are less effective in common daily practice among patients with hypercholesterolemia: The REALITY-PHARMO study. Curr Med Res Opin 2004;20 (7):1025-33.
23. Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: A US managed care study. Curr Med Res Opin 2008;24(7):1987-2000.
24. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005; 162:199-205.
25. Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clin Proc 2008;83 (12):1316-25.
26. Thiebaud P, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: The case of statin treatment. Am J Manag Care 2005;11(11):670-4.
27. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004;22(suppl 3):13-23.
28. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart 2004;90(9):1065-6.
29. van der Vaart R, Kroon JD. Beoogde besparing op statines is onzeker. Meeste omzettingen blijken niet dosisequipotent [Intended savings on statins are uncertain. Most switches prove not to be to equipotent doses]. Pharmaceutisch Weekblad: SFK Stichting Farmaceutische Kengetallen, 144 (18):26-30. 2009.
30. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-The PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14.
31. Krasuski RA, Doeppenschmidt D, Henry JS, et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: The CAPISH study. Mayo Clin Proc 2005;80 (9):1163-8.
32. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000;25(6):445-51.
33. Goldberg KC, Melnyk SD, Simel DL. Overcoming inertia: Improvement in achieving target low-density lipoprotein cholesterol. Am J Manag Care 2007;13(9):530-4.
34. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135(9):825-34.
35. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005;294(19):2437-45.
36. Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: A large database analysis of managed care plans in the United States. Clin Ther 2008;30(1):195-205.
37. Phillips JO. Switching statins: The impact on patient outcomes. Br J Cardiol 2007;14:280-5.
38. Kostapanos MS, Milionis HJ, Filippatos TD, et al. Dosedependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther 2009;14(1):5-13.